QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=E9C6CF2687D0337E3847E2F5AF5E8F81;jsessionid=6AB2D498CBA25EB3CFE3A78AFCB91067;jsessionid=1BFCBA7E4AF590FC62DADD3A7AA59E75;jsessionid=520AB13D2A92E5FCD64C92B53C29CEF4;jsessionid=1B4A12527840888EB67A8D4657E8F0F8;jsessionid=B339B2C09281759354CE45B70023E295 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=E9C6CF2687D0337E3847E2F5AF5E8F81;jsessionid=6AB2D498CBA25EB3CFE3A78AFCB91067;jsessionid=1BFCBA7E4AF590FC62DADD3A7AA59E75;jsessionid=520AB13D2A92E5FCD64C92B53C29CEF4;jsessionid=1B4A12527840888EB67A8D4657E8F0F8;jsessionid=B339B2C09281759354CE45B70023E295